Chinese biosimilars developer Shanghai Henlius Biotech has trumpeted its “milestone” first shipment to the US, with the delivery of its trastuzumab biosimilar marking the firm’s “first commercial supply to North America, representing a significant breakthrough in its global expansion.”
Henlius’ trastuzumab – known as Hanquyou in its domestic market and Zercepac in Europe – is commercialized in the US as Hercessi via partner Accord Biopharma, following US Food and Drug Administration approval earlier this year. A more recent
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?